These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30420593)

  • 41. Expression of telomerase reverse transcriptase in peripheral T-cell lymphoma.
    Arakawa F; Miyoshi H; Yoshida N; Nakashima K; Watatani Y; Furuta T; Yamada K; Moritsubo M; Takeuchi M; Yanagida E; Shimasaki Y; Kohno K; Kataoka K; Ohshima K
    Cancer Med; 2021 Oct; 10(19):6786-6794. PubMed ID: 34477310
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma.
    Zhang H; Lv H; Jia X; Hu G; Kong L; Zhang T; Li L; Pan Y; Zhai Q; Meng B; Wang X; Wang H; Wang X
    Oncol Lett; 2019 Aug; 18(2):1415-1423. PubMed ID: 31423206
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.
    Rajendran P; Li F; Shanmugam MK; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Sethi G
    J Cell Physiol; 2012 May; 227(5):2184-95. PubMed ID: 21792937
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma.
    Nelson M; Horsman DE; Weisenburger DD; Gascoyne RD; Dave BJ; Loberiza FR; Ludkovski O; Savage KJ; Armitage JO; Sanger WG
    Br J Haematol; 2008 May; 141(4):461-9. PubMed ID: 18341637
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma.
    Hong JY; Hong ME; Choi MK; Chang W; Do IG; Jo JS; Jung SH; Park S; Kim SJ; Ko YH; Kim WS
    Anticancer Res; 2015 Apr; 35(4):2465-74. PubMed ID: 25862915
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant.
    Jagasia M; Morgan D; Goodman S; Hamilton K; Kinney M; Shyr Y; Stein R; Zic J; Greer J
    Leuk Lymphoma; 2004 Nov; 45(11):2261-7. PubMed ID: 15512815
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations.
    Zettl A; Rüdiger T; Konrad MA; Chott A; Simonitsch-Klupp I; Sonnen R; Müller-Hermelink HK; Ott G
    Am J Pathol; 2004 May; 164(5):1837-48. PubMed ID: 15111330
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Peripheral T-cell lymphomas.
    Savage KJ
    Blood Rev; 2007 Jul; 21(4):201-16. PubMed ID: 17512649
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
    Gleeson M; Peckitt C; Cunningham D; Gibb A; Hawkes EA; Back M; Yasar B; Foley K; Lee R; Dash J; Johnson H; O'Hara C; Wotherspoon A; Attygalle A; Menasce L; Shenjere P; Potter M; Ethell ME; Dearden C; Radford J; Chau I; Linton K
    Leuk Lymphoma; 2018 Jul; 59(7):1586-1595. PubMed ID: 29119842
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FOXP3-positive T-cell lymphomas in non-HTLV1 carriers include ALK-negative anaplastic large cell lymphoma: expanding the spectrum of T-cell lymphomas with regulatory phenotype.
    Ferreira CR; Zhao S; Sahoo MK; Pinsky B; Weber J; Lage LAPC; Pereira J; Zerbini MCN; Natkunam Y
    Hum Pathol; 2018 Oct; 80():138-144. PubMed ID: 29898383
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.
    Reboursiere E; Le Bras F; Herbaux C; Gyan E; Clavert A; Morschhauser F; Malak S; Sibon D; Broussais F; Braun T; Fornecker LM; Garidi R; Tricot S; Houot R; Joly B; Abarah W; Choufi B; Pham AD; Gac AC; Fruchart C; Marin E; Safar V; Parcelier A; Maisonneuve H; Bachy E; Cartron G; Jaccard A; Tournilhac O; Rossi C; Schirmer L; Martignoles JA; Gaulard P; Tilly H; Damaj G;
    Oncotarget; 2016 Dec; 7(51):85573-85583. PubMed ID: 27458168
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The prognostic significance of lymphopenia in peripheral T-cell and natural killer/T-cell lymphomas: a study of 826 cases from the International Peripheral T-cell Lymphoma Project.
    Mitrovic Z; Perry AM; Suzumiya J; Armitage JO; Au WY; Coiffier B; Holte H; Jaffe ES; Monserrat E; Rajan SK; Savage KJ; Tobinai K; Vose JM; Weisenburger DD
    Am J Hematol; 2012 Aug; 87(8):790-4. PubMed ID: 22488678
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aggressive peripheral T-cell lymphomas (specified and unspecified types).
    Savage KJ
    Hematology Am Soc Hematol Educ Program; 2005; ():267-77. PubMed ID: 16304391
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation.
    Rassidakis GZ; Jones D; Lai R; Ramalingam P; Sarris AH; McDonnell TJ; Medeiros LJ
    J Pathol; 2003 Jun; 200(2):240-8. PubMed ID: 12754745
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
    Zhang P; Zhang M
    Clin Epigenetics; 2020 Nov; 12(1):169. PubMed ID: 33160401
    [TBL] [Abstract][Full Text] [Related]  

  • 56. From empiric to mechanism-based therapy for peripheral T cell lymphoma.
    Intlekofer AM; Younes A
    Int J Hematol; 2014 Mar; 99(3):249-62. PubMed ID: 24510453
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peripheral T-cell lymphoma with follicular T-cell markers.
    Rodríguez-Pinilla SM; Atienza L; Murillo C; Pérez-Rodríguez A; Montes-Moreno S; Roncador G; Pérez-Seoane C; Domínguez P; Camacho FI; Piris MA
    Am J Surg Pathol; 2008 Dec; 32(12):1787-99. PubMed ID: 18779728
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience.
    Rohlfing S; Dietrich S; Witzens-Harig M; Hegenbart U; Schönland S; Luft T; Ho AD; Dreger P
    Ann Hematol; 2018 Jul; 97(7):1241-1250. PubMed ID: 29549411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy.
    Chihara D; Oki Y; Ine S; Yamamoto K; Kato H; Taji H; Kagami Y; Yatabe Y; Nakamura S; Morishima Y
    Leuk Lymphoma; 2009 Dec; 50(12):1999-2004. PubMed ID: 19860627
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer.
    Berishaj M; Gao SP; Ahmed S; Leslie K; Al-Ahmadie H; Gerald WL; Bornmann W; Bromberg JF
    Breast Cancer Res; 2007; 9(3):R32. PubMed ID: 17531096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.